Mon, 27 Oct 2014 13:11:41 GMT ~ Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
[at noodls] - CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that ...
Link: http://www.otcmarkets.com/stock/AGIO/company-info Ticker: $AGIO OTC Market Place: Not Available CIK code: not found Company name: Agios Pharmaceuticals, Inc. Incorporated In:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
$AGIO share structure
## source: otcmarkets.com
Market Value: Not Available Shares Outstanding: Not Available Float: Not Available Authorized Shares: Not Available Par Value: Not Available $AGIO extra dd links